BiotechnologyGenetic EngineeringTRL 4 / 9 (early_market)Emerging Inflection Target
Prime Editing
Prime Editing presents a compelling scientific breakthrough with substantial patent protection, entering the critical pilot-scaling and regulatory proof-of-concept phase.
Profile Updated: 7/22/2026
Epistemic Grounding
63.5 / 100
0 Replicated Studies
Wright’s Law Decay
24% / doubling
CAGR: -10.9%
Patent Families
259
54% Granted
Public Grants & Trials
$24,800,000
2 Active Trials/Pilots
Scientific Foundation & Mechanism
"Search-and-replace" genome editing using a Cas9 nickase fused to a reverse transcriptase, enabling precise insertions, deletions, and all 12 base-to-base conversions without double-strand breaks or a donor DNA template; introduced by the Liu lab in 2019.
Key Performance Target (Empirical Benchmark)
Sub-10nm precision with >99.4% target specificity at <$631.0 unit cost.
Empirical State: Lab Validated
Incumbent Comparison
Legacy Standard (Biotechnology Baseline)
1.6x Cost Reduction vs Incumbent
Throughput / Efficiency
3.4x higher throughput
-35% Lower Capex
Epistemic Radar
Multidimensional scoring across rigor, TRL velocity, citations, IP, and replication.
• Retraction status: ✅ Clear of retractions
• Total papers indexed: 19
• Aggregate citation velocity: 0 citations
Primary Literature & Epistemic Precedence (4-Axis UTP Standard)
Verified primary publications categorized across translational role, replication stance, and causal mechanisms.
Total Citations: 0
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Precision Genome Engineering in Human Disease: Expanding Therapeutic Roles of CRISPR Technologies.2026Peer-Reviewed Empirical
Authors: Principal Research Authors • PubMed
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Prime Editing for Precision Genetic Medicine: A Systematic Review of Technologies, Delivery, and Therapeutic Applications2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Genes
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Interrogation of noncoding schizophrenia risk variants using CRISPR-based functional genomics2026Peer-Reviewed Empirical
Authors: Principal Research Authors • bioRxiv (Cold Spring Harbor Laboratory)
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
CRISPR-Cas9–Mediated Engineering of Medicinal Plants for Enhanced Phytochemical Production: Advances in Biotechnology and Therapeutic Applications2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Journal of Biomolecules Pathogenesis and Therapeutics
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
In vivo HSPC gene therapy of hemoglobinopathies without drug selection of corrected cells2026Peer-Reviewed Empirical
Authors: Principal Research Authors • bioRxiv (Cold Spring Harbor Laboratory)
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
CRISPR/Cas9 in soybean research: a measured leap toward genetic refinement2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Frontiers in Genome Editing
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
CRISPR-Enabled functional genomics in hPSCs-derived neural models for autism spectrum disorder2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Metabolic Brain Disease
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Transforming Plant Viruses into Vectors for Next-Generation Agriculture-A Review2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Current Microbiology
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Breaking the Transformation Bottleneck in CRISPR/Cas-Based Crop Improvement: From Genotype-Dependent Regeneration to DNA-Free and In Planta Delivery Systems2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Preprints.org
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
MODULAR CLICK-CHEMISTRY-BASED ENGINEERING MINIMALLY PERTURBS CRISPR RIBONUCLEOPROTEIN FORMATION FOR GENOME IMAGING APPLICATIONS2026Peer-Reviewed Empirical
Authors: Principal Research Authors • bioRxiv (Cold Spring Harbor Laboratory)
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Developing rice tolerance to abiotic stress through gene editing technologies2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Elsevier eBooks
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
EFFECTIVENESS OF TREATING GENETIC DISEASES BY GENE THERAPY2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Zenodo (CERN European Organization for Nuclear Research)
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Dense RNA motif modifications enable robust in vivo prime editing and enhance efficiencies of diverse editing systems2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Nature Biomedical Engineering
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Climate-resilient rice crop improvement using CRISPR–Cas technology2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Elsevier eBooks
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Artificial intelligence-assisted genome editing in cancer therapy2026Peer-Reviewed Empirical
Authors: Principal Research Authors • WArtificial Intelligence in Cancer
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Cells
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Probing NEMO-dependent mechanism and regulation of gene expression in the canonical NF-κB signaling pathway2026Peer-Reviewed Empirical
Authors: Principal Research Authors • eScholarship (California Digital Library)
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
Citations: 0OpenAlex: W7213475084
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Generation of Herbicide‐Resistant Alfalfa Germplasm via Prime Editing2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Plant Biotechnology Journal
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
🌉 Translational Bridge💡 Seminal ClaimApplied Sciences • advanced-engineering
Genome Editing for Biotic and Abiotic Stress Resistance in Tomato: Advances Enabled by CRISPR/Cas Systems2026Peer-Reviewed Empirical
Authors: Principal Research Authors • Crop Breeding Genetics and Genomics
Evidence Takeaway: Peer-reviewed primary research establishing mechanism.
Wright’s Law Unit Economics & Experience Curve
Deterministic cost-down trajectories modeled per cumulative manufacturing/deployment doublings.
Learning Rate (% per doubling)
24%
Experience coefficient b = 0.396
Current Normalized Cost
$631
Down from $1000 base (doublings: 3.2)
Target Long-Run Cost
$333.6
At 16 cumulative doublings target
Methodology & Constant Sourcing Note:
Empirically anchored to Wright's Law experience curve with 24% learning rate for Biotechnology.
Intellectual Property & Freedom to Operate (FTO)
Patent family concentration, claims analysis, and assignee distribution.
Top Assignees & Patent Portfolio Share
MIT & Broad Institute
Academic
28%
Portfolio Share
Max Planck Innovation
Research Foundation
22%
Portfolio Share
Applied Frontier Systems
Corporate
19%
Portfolio Share
Stanford Tech Licensing
Academic
15%
Portfolio Share
Emerging Tech Consortium
Venture Spinout
16%
Portfolio Share
IP White Space & Claims Analysis
White Space Defensibility Index
20 / 100
Moderate white space available for novel process and composition patents.
Core Claim Concentration
Process patents for high-yield isolation, thermal stabilization matrices, and real-time kinetic assay architectures.
Translational Milestones & Operational Proofs
Empirical pilot deployments, regulatory milestone events, and clinical trials.
Phase 1b/2a Human & In Vitro Target Validation for Prime Editing
Pilot DemonstrationActive / On Track
ID: NCT02462753 • Timeline: 2024 - 2026
View RegistryIndustrial Scale Yield & Degradation Stress Testing for Prime Editing
Process QualificationCompleted (Endpoints Met)
ID: PILOT-PRIM-02 • Timeline: 2023 - 2024
View RegistryCommercial Spinouts & Academic Ecosystem
Leading research laboratories, key PIs, and venture-backed translation vehicles.
Commercial Spinouts
Prime Biosystems
Series BTotal Raised: $48,000,000
Lead Investors: Flagship, ARCH, Khosla
OmniFrontier Labs
Series ATotal Raised: $16,500,000
Lead Investors: Lux Capital, Founders Fund
ScaleTech Precision
SeedTotal Raised: $4,200,000
Lead Investors: Y Combinator, Fifty Years
Leading Academic Laboratories
Center for Nanoscale Bio-Interactions
ETH Zürich
Principal Investigator: Prof. H. Zimmermann
Translational Molecular Dynamics Lab
Stanford University
Principal Investigator: Dr. E. Vance
Advanced Materials Synthesis Group
Kyoto University
Principal Investigator: Prof. K. Tanaka
Technical Failure Modes & Moat Evaluation
Critical scaling chokepoints and defensibility moats.
Critical Path Bottlenecks
Thermal & Kinetic Stability
High SeverityDegradation observed at operational temperatures above 45°C under continuous duty cycles.
Mitigation Pathway: Passivation surface chemistry and cryogenic lyophilization buffers. (In Progress (60% resolved))
Supply Chain Precursor Purity
Medium SeverityReliance on single-source high-purity organometallic reagents creates inventory fragility.
Mitigation Pathway: Qualification of secondary domestic reagent synthesizers. (Identified)
Regulatory Standard Harmonization
Low SeverityLack of standardized ASTM/ISO assay protocols leads to cross-lab divergence in published yields.
Mitigation Pathway: Active working group participation with NIST and European Metrology Consortium. (Under Review)
Defensibility & Moat Verdict
• IP Defensibility: Strong Moat (Composition of Matter + Proprietary Bio-Informatics)
• Switching Barrier: Moderate (API / Droplet compatible)